TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34001215
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical in appearance to camostat mesylate capsules, one capsule taken each morning, afternoon, and evening on days 1-7)
Study: 34740607
Drug: Baked milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baked milk oral immunotherapy (BMOIT)
Study: 34642494
Drug: Bepirovirsen 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepirovirsen 300 mg
Study: 34642494
Drug: Bepirovirsen 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bepirovirsen 150 mg
Study: 34642494
Drug: Stable NA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable NA therapy with Bepirovirsen
Study: 36867504
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg apixaban
Study: 35429485
Drug: Once-daily risdiplam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily risdiplam
Study: 32127848
Drug: Ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.5 mg/kg intravenously
Study: 32127848
Drug: Fentanyl 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1.0 µg/kg intravenously
Study: 35648305
Drug: Qizi Yusi
Normalized name: Yusimry
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Qizi Yusi Pill (QYP)
Study: 32207010
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cooking fuels
Study: 33001422
Drug: ACEI (Angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEI (Angiotensin Converting Enzyme Inhibitor)
Study: 33001422
Drug: ARB (Angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB (Angiotensin II Type I Receptor Blocker)
Study: 32660143
Drug: Iprodione treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iprodione treatment on mutant M0
Study: 32660143
Drug: Iprodione treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iprodione treatment on mutant M1
Study: 32660143
Drug: Iprodione treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iprodione treatment on wild type W0
Study: 34305036
Drug: Acidulated phosphate
Normalized name: Acidulated Phosphate Fluoride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acidulated phosphate fluoride gel (APF)
Study: 34305036
Drug: Neutral fluoride
Normalized name: SODIUM FLUORIDE 0.9 mg in 1 g DENTAL AEROSOL, FOAM [KOLORZ NEUTRAL FLUORIDE FOAM TRIPLE MINT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neutral fluoride gel (NGel)
Study: 34305036
Drug: Without fluoride
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Without fluoride treatment (control)
Study: 39145520
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral iron supplementation
Study: 36078489
Drug: Concurrent training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent training group (CTG)
Study: 34587808
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g intravenous (IV) tranexamic acid (TXA) at the time of surgery and an additional 24-hour postoperative oral regime of four 1 g doses
Study: 34587808
Drug: Single preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single preoperative intravenous dose of 1 g TXA
Study: 34587808
Drug: No TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: No TXA administered
Study: 34800364
Drug: NVX-CoV2373 plus
Normalized name: NVX-CoV2373
DrugBank: Nuvaxovid (DB15810)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NVX-CoV2373 plus the influenza vaccine
Study: 34800364
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus the influenza vaccine
Study: 33514449
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (bempedoic acid 180 mg, ezetimibe 10 mg, atorvastatin 20 mg)
Study: 32335844
Drug: BIIB059 (anti-BDCA2
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIIB059 (anti-BDCA2 monoclonal antibody) administered intravenously and subcutaneously, dosage not specified.
Study: 34251873
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with cisplatin (100 mg/m2) and docetaxel (85 mg/m2) followed by durvalumab (750 mg)
Study: 34251873
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with cisplatin and docetaxel
Study: 34251873
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy followed by durvalumab
Study: 33129910
Drug: Chemoradiation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiation therapy (2 concurrent cycles of cisplatin followed by 4 cycles of carboplatin/paclitaxel)
Study: 33793460
Drug: mRNA BNT162b2
Normalized name: SARS-CoV-2 vaccine, mRNA BNT162b2 bivalent original & OMICRON (BA.4/.5) 0.3 ML Injection, 12y+ (EUA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA BNT162b2 and mRNA-1273 COVID-19 vaccines (full immunization, ≥14 days after second dose)
Study: 33793460
Drug: mRNA BNT162b2
Normalized name: SARS-CoV-2 vaccine, mRNA BNT162b2 bivalent original & OMICRON (BA.4/.5) 0.3 ML Injection, 12y+ (EUA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA BNT162b2 and mRNA-1273 COVID-19 vaccines (partial immunization, ≥14 days after first dose and before second dose)
Study: 32876987
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (30 g in 200 mL warm water at fasting time for 4 weeks)
Study: 32876987
Drug: Placebo (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (30 g in 200 mL warm water at fasting time for 4 weeks)
Study: 36079822
Drug: Nutritional supplements,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplements, diet education, and standard care
Study: 33354755
Drug: Pharmacist intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist intervention involving medication therapy problem identification and recommendations
Study: 33354755
Drug: Medication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication therapy problems related to indication, effectiveness, and safety
Study: 36003379
Drug: Hypomethylating agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypomethylating agents (HMAs)
Study: 32573121
Drug: Drainage–injection–pneumoretinopexy (DIP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drainage–injection–pneumoretinopexy (DIP)
Study: 34050594
Drug: High-dose losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose losartan
Study: 34050594
Drug: Low-dose losartan
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose losartan
Study: 33966293
Drug: Cumulative melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cumulative melphalan exposure among cases (median 988 mg; IQR 644-1640)
Study: 33966293
Drug: Cumulative melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cumulative melphalan exposure among controls (median 578 mg; IQR 360-967)
Study: 32248243
Drug: GAD-alum (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD-alum (20 μg, administered twice or three times)
Study: 33735594
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (Ferinject) 1,000 mg or 15 mg/kg if weight <66.7 kg
Study: 33735594
Drug: Iron dextran
Normalized name: Iron Dextran
DrugBank: Iron Dextran (DB00893)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron dextran (Cosmofer) 20 mg iron/kg body weight
Study: 35873404
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of ashwagandha root extract twice daily
Study: 32583313
Drug: Allisartan 240
Normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allisartan 240 mg/day and lifestyle modification
Study: 33589590
Drug: Venlafaxine extended-release
Normalized name: Desvenlafaxine Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine extended-release for 12 weeks
Study: 33000160
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g oral l-histidine daily for 8 weeks
Study: 33000160
Drug: 0.8 g
Normalized name: Alcohol 0.8 g in 1 mL TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g l-histidine daily for 12 weeks
Study: 33000160
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g l-histidine daily
Study: 35389028
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination cream alone (control group)
Study: 35389028
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination cream + microneedling
Study: 35389028
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination cream + tranexamic acid (TA 250 mg twice daily)
Study: 35389028
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination cream + microneedling + tranexamic acid
Study: 36092537
Drug: Low-volume split-dose
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume split-dose regimen two (1.5L PEG after dinner, 0.75L PEG 4 hours before colonoscopy)
Study: 36092537
Drug: Low-volume split-dose
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume split-dose regimen one (0.75L PEG after dinner, 1.5L PEG 4 hours before colonoscopy)
Study: 32894785
Drug: Siltuximab (anti-IL-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siltuximab (anti-IL-6 therapy)
Study: 36396412
Drug: Instructing parents
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instructing parents to read daily
Study: 35960896
Drug: Gefitinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib plus chemotherapy (GCP: gefitinib 250 mg orally once daily combined with carboplatin plus pemetrexed in a 3-week cycle for six cycles followed by concurrent gefitinib and pemetrexed maintenance)
Study: 35960896
Drug: Gefitinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib (250 mg orally, once daily)
Study: 35960896
Drug: Gefitinib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib plus chemotherapy (GCP)
Study: 33793273
Drug: All enrolled
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All enrolled parents (treatment and control)
Study: 32811749
Drug: Integrative medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative medicine visits
Study: 32786325
Drug: Sparse measurements
Normalized name: sparsentan
DrugBank: Sparsentan (DB12548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sparse measurements of library molecules using a machine learning algorithm to predict molecular function.
Study: 32216594
Drug: Orange juice
Normalized name: Orange juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orange juice (pH = 3.5) with Phenobarbital (2.5 mg/kg)
Study: 32216594
Drug: Mineral water
Normalized name: mineral water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineral water (neutral pH) with Phenobarbital (2.5 mg/kg)
Study: 35458200
Drug: High-dose kawakawa
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose kawakawa tea (4 g/250 mL water)
Study: 34882729
Drug: Medicine ball
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicine ball throws protocol (3 sets of 6 repetitions using a 2 kg ball, throwing at maximal speed)
Study: 34360184
Drug: G% (1RM
Approvals — FDA: no, EMA: no, PMDA: no
Description: G% (1RM test group)
Study: 35945770
Drug: Supervised physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised physical therapy exercise program plus 20 minutes PBMT (650 nm, 5 mW, 1 cm², 6 Joules, 3 sessions/week for 8 weeks) plus traditional medical treatment
Study: 35945770
Drug: PBMT (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBMT (same protocol as Group A, 3 sessions/week for 8 weeks) plus traditional medical treatment
Study: 35276223
Drug: Adalimumab monotherapy
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab monotherapy (ADL)
Study: 34727741
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis alone
Study: 34428930
Drug: Control (Intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Intravenous thrombolysis alone)
Study: 33305723
Drug: Posaconazole injection
Normalized name: posaconazole Injection
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole injection 100 mg
Study: 33305723
Drug: Posaconazole injection
Normalized name: posaconazole Injection
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole injection 200 mg
Study: 33305723
Drug: Posaconazole injection
Normalized name: posaconazole Injection
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole injection 300 mg
Study: 616118370
Drug: Sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham injection (control)
Study: 33629803
Drug: Autoregulated heavy
Normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autoregulated heavy slow resistance training (HSRT) combined with extracorporeal shockwave therapy (ESWT)
Study: 36192126
Drug: Short-course outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-course outpatient antibiotic therapy
Study: 36192126
Drug: Standard-course outpatient
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-course outpatient antibiotic therapy
Study: 34014695
Drug: Tele.TAnDem (telephone-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tele.TAnDem (telephone-based cognitive-behavioral therapy) consisting of 12 sessions over 6 months
Study: 36821354
Drug: Avelumab 10
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab 10 mg/kg every 2 weeks
Study: 35856817
Drug: Oral Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral Methotrexate 7.5 mg weekly for a maximum of 12 weeks
Study: 35856817
Drug: Oral Mini
Normalized name: oxymetazoline hydrochloride Nasal Solution [Iliadin Mini]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Mini Pulse Betamethasone 3 mg weekly for a maximum of 12 weeks
Study: 35921241
Drug: Structured exercise
Normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured exercise programme consisting of close kinetic chain (CKC) exercises 2 days a week for 12 weeks, in addition to prophylactic treatment.
Study: 35921241
Drug: Conventional Treatment
Normalized name: PECTIN 11.5 mg in 7 g ORAL LOZENGE [Lolleez Birthday Cake - Conventional]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Treatment Group (CTG) received exercise training as described in the published literature.
Study: 35921241
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group (CG) continued to receive prophylactic treatment during the study period.
Study: 32266380
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of aspirin twice daily
Study: 32266380
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of aspirin thrice daily
Study: 35665724
Drug: Integrative Korean
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative Korean medicine treatment (IMKT) + Non-resistance manual therapy (NRT)
Study: 35665724
Drug: Integrative Korean
Normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative Korean medicine treatment (IMKT)
Study: 35537105
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy as per protocol
Study: 34524157
Drug: Phenylephrine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylephrine (50 μg)
Study: 34524157
Drug: Norepinephrine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norepinephrine (4 μg)
Study: 36105122
Drug: BCAA+FO supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA+FO supplement group (n=10)
Study: 33619708
Drug: Postoperative oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative oxycodone combined with nonopioid analgesics
Study: 32555990
Drug: Intrathyroid injection
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathyroid injection of dexamethasone (IID)
Study: 34664816
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600 mg, twice a day
Study: 32924685
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg bolus before induction and 3 µg/kg/min infusion during surgery)
Study: 32924685
Drug: Saline (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.5 mg/kg bolus before induction and 3 µg/kg/min infusion during surgery)
Study: 33860177
Drug: Psilocybin (20‐30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (20‐30 mg/70 kg) with overtone-based music
Study: 33860177
Drug: Psilocybin (20‐30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (20‐30 mg/70 kg) with Western classical music
Study: 33860177
Drug: Psilocybin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (30 mg/70 kg) with chosen music (overtone-based or Western classical)
Study: 32022647
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) and Psychodynamic Therapy (PDT)
Study: 32826769
Drug: Timolol 0.5%
Normalized name: Timolol 0.5% Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timolol 0.5% twice-daily
Study: 32680548
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein supplementation (30 g/day) with hypocaloric diet
Study: 33620419
Drug: Control (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (placebo or no treatment not specified)
Study: 35899977
Drug: Apomorphine sublingual
Normalized name: apomorphine Sublingual Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine sublingual film (SL‐APO)
Study: 35899977
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg, positive control)
Study: 35816069
Drug: Nutraceutical supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceutical supplement
Study: 35816069
Drug: Nutraceutical supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceutical supplement (after transitioning from placebo)
Study: 33067310
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone 2 mg/kg (maximum 40 mg), once daily for 3 days
Study: 34622597
Drug: Low Dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose - Deep Learning (LD-DL)
Study: 34622597
Drug: Normal Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Dose - Iterative Reconstruction (ND-IR)
Study: 34622597
Drug: Low Dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose - Filtered Back Projection (LD-FBP)
Study: 34622597
Drug: Low Dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose - Iterative Reconstruction (LD-IR)
Study: 36122260
Drug: Ultrasound-guided bilateral
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided bilateral retrolaminar block with 20 mL of 0.25% bupivacaine and 5 µg/mL adrenaline (1:200000)
Study: 36122260
Drug: Ultrasound-guided thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided thoracic epidural analgesia with 20 mL of 0.25% bupivacaine and 5 µg/mL adrenaline (1:200000)
Study: 33382189
Drug: HBsAg-positive with
Normalized name: HBSAG
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBsAg-positive with high HBV DNA (≥2000 IU/ml)
Study: 34773923
Drug: GSK3358699 (1-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3358699 (1-40 mg)
Study: 34773923
Drug: GSK3358699 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3358699 (10 mg)
Study: 34773923
Drug: GSK3358699 (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3358699 (20-40 mg)
Study: 34773923
Drug: GSK3358699 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3358699 (40 mg)
Study: 32703316
Drug: medication alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: medication alone
Study: 33752148
Drug: Single-dose carbohydrates
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose carbohydrates (administered 2–3 h before surgery)
Study: 33752148
Drug: Double-dose carbohydrates
Normalized name: CARBOHYDRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose carbohydrates (administered 10 h before surgery and 2–3 h before surgery)
Study: 33752148
Drug: Single-dose carbohydrates
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose carbohydrates
Study: 33752148
Drug: Double-dose carbohydrates
Normalized name: CARBOHYDRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose carbohydrates
Study: 32859978
Drug: DEGs associated
Normalized name: HEPATITIS ASSOCIATED ANTIBODY
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEGs associated with thioredoxin system and iron ion metabolism